Emerging Data Regarding Maintenance Therapy in Multiple Myeloma

This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Understand the existing and emerging clinical research data and apply it to make evidence-based selection of appropriate maintenance therapy for patients with MM
  • Counsel patients with MM who are being considered for maintenance therapy about its safety and efficacy and the possibility of participation in ongoing clinical trials
Additional information
Supporters: 

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.50 Participation
  • 0.57 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
11/09/2012
Course expires: 
11/09/2013
Cost:
$0.00

George Somlo, MD
City of Hope Comprehensive Cancer Center

Available Credit

  • 0.50 Participation
  • 0.57 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician

Accreditation Period

Course opens: 
11/09/2012
Course expires: 
11/09/2013

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing